APA

Zeidner J. F., Foster M. C., Blackford A. L., Litzow M. R., Morris L. E., Strickland S. A., Lancet J. E., Bose P., Levy M. Y., Tibes R., Gojo I., Gocke C. D., Rosner G. L., Little R. F., Wright J. J., Doyle L. A., Smith B. D. & Karp J. E. (20190403). Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). : Leukemia research.

Chicago

Zeidner Joshua F, Foster Matthew C, Blackford Amanda L, Litzow Mark R, Morris Lawrence E, Strickland Stephen A, Lancet Jeffrey E, Bose Prithviraj, Levy M Yair, Tibes Raoul, Gojo Ivana, Gocke Christopher D, Rosner Gary L, Little Richard F, Wright John J, Doyle L Austin, Smith B Douglas and Karp Judith E. 20190403. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). : Leukemia research.

Harvard

Zeidner J. F., Foster M. C., Blackford A. L., Litzow M. R., Morris L. E., Strickland S. A., Lancet J. E., Bose P., Levy M. Y., Tibes R., Gojo I., Gocke C. D., Rosner G. L., Little R. F., Wright J. J., Doyle L. A., Smith B. D. and Karp J. E. (20190403). Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). : Leukemia research.

MLA

Zeidner Joshua F, Foster Matthew C, Blackford Amanda L, Litzow Mark R, Morris Lawrence E, Strickland Stephen A, Lancet Jeffrey E, Bose Prithviraj, Levy M Yair, Tibes Raoul, Gojo Ivana, Gocke Christopher D, Rosner Gary L, Little Richard F, Wright John J, Doyle L Austin, Smith B Douglas and Karp Judith E. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). : Leukemia research. 20190403.